|
Age (year) median, (IQR)
|
63.5 (55–71)
|
63 (54–69)
|
0.57
|
|
Gender, male (n, %)
|
130 (71)
|
78 (66)
|
0.48
|
|
Comorbidities (n, %)
|
|
Cardiovascular
|
93 (58)
|
58 (56)
|
0.8
|
|
Pulmonary
|
61 (38)
|
43 (41)
|
0.69
|
|
Renal
|
28 (18)
|
21 (20)
|
0.72
|
|
Charlson Index median, (IQR) missing data = 36
|
5 (4–7)
|
5 (3–6)
|
0.42
|
|
Underlying disease (n, %)
|
|
Haematological malignancy, n (%)
|
139 (75)
|
86 (73)
|
0.36
|
|
Allogeneic stem cell transplant, n (%)
|
19 (11)
|
9 (8)
|
0.56
|
|
Performance status > 2 (n, %)
|
63 (34)
|
42 (36)
|
0.13
|
|
Number of quadrant involved = 3 or 4 (n,%) missing data = 56
|
68 (45)
|
54 (57)
|
0.09
|
|
Aetiology of ARF (n, %)
| | |
0.84
|
|
Bacterial or viral pneumonia
|
92 (50)
|
58 (49)
| |
|
Opportunistic infection
|
29 (16)
|
25 (21)
| |
|
Lung involvement by the underlying disease Drug-related pulmonary toxicity
|
16 (9)
|
10 (8)
| |
|
Other identified causes
|
33 (18)
|
19 (16)
| |
|
No identified cause
|
12 (6)
|
5 (4)
| |
|
Neutropenia recovery at admission (n,%)
|
18 (10)
|
7 (6)
|
0.33
|
|
SOFA day 1 missing data = 25
|
4 (2–7)
|
4.5 (2–7)
|
0.94
|
|
RR 30 min after randomization median, (IQR) missing data = 14
|
25 (21–30)
|
31 (25–35)
|
< 0.001
|
|
Oxygen flow > 9 L/min at randomization, n (%)
|
94 (51)
|
72 (13)
|
0.49
|
|
NIV group
|
30 (16)
|
15 (13)
|
0.45
|
|
Glasgow score at 15 at Day 1 (n, %)
|
160 (87)
|
97 (82)
|
0.52
|
|
Outcomes
|
|
Intubated during ICU (n, %)
|
55 (30)
|
60 (51)
|
< 0.001
|
|
Length between ICU admission and intubation
|
3 (1–4.5)
|
2 (1–2.5)
|
0.005
|
|
Vasopressor during ICU stay, n (%)
|
71 (39)
|
62 (52)
|
0.03
|
|
Renal Replacement Therapy during ICU stay, n (%)
|
30 (16)
|
19 (16)
|
0.32
|
|
End of life decision during ICU stay, n (%)
|
47 (26)
|
47 (36)
|
0.02
|
|
Day 28 mortality (n,%)
|
39 (21)
|
44 (37)
|
0.003
|
|
Length of ICU stay, median (IQR) survival patient (n = 219)
|
8 (5–13)
|
10 (6–17.7)
|
0.02
|
|
Length of hospital stay median, (IQR) (n = 302
|
24 (15–38)
|
22 (12–40)
|
0.52
|
